Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Moseley

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Optics Express|October 19, 2017
Dual focus polarisation splitting lensPaul Moseley, Giorgio Savini, Jin Zhang, et al.
Pathology Oncology Research : POR|December 22, 2009
T cell density and location can influence the prognosis of ovarian cancerAhmad Al-Attar, Mohamed Shehata, Lindy Durrant, et al.
Plos One|March 2, 2013
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cellsRebeka Sultana, Tarek Abdel-Fatah, Christina Perry, et al.
Breast Cancer Research and Treatment|January 2, 2014
Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancerTarek M A Abdel-Fatah, Christina Perry, Paul Moseley, et al.
Cancer Letters|November 1, 2019
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancersReem Ali, Muslim Alabdullah, Adel Alblihy, et al.
BBA Clinical|December 18, 2015
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersTarek M A Abdel-Fatah, Arvind Arora, Paul Moseley, et al.
Breast Cancer Research and Treatment|November 21, 2013
Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapyTarek M A Abdel-Fatah, Nada Albarakati, Lara Bowell, et al.
Oncotarget|January 20, 2018
The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2Tarek M A Abdel-Fatah, Robert C Rees, A Graham Pockley, et al.
Breast Cancer Research and Treatment|June 29, 2014
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancersTarek Abdel-Fatah, Arvind Arora, Devika Agarwal, et al.
Gynecologic Oncology|February 25, 2019
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancersKatia A Mesquita, Muslim Alabdullah, Michaela Griffin, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Optics Express|October 19, 2017
Dual focus polarisation splitting lensPaul Moseley, Giorgio Savini, Jin Zhang, et al.
Pathology Oncology Research : POR|December 22, 2009
T cell density and location can influence the prognosis of ovarian cancerAhmad Al-Attar, Mohamed Shehata, Lindy Durrant, et al.
Plos One|March 2, 2013
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cellsRebeka Sultana, Tarek Abdel-Fatah, Christina Perry, et al.
Breast Cancer Research and Treatment|January 2, 2014
Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancerTarek M A Abdel-Fatah, Christina Perry, Paul Moseley, et al.
Cancer Letters|November 1, 2019
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancersReem Ali, Muslim Alabdullah, Adel Alblihy, et al.
BBA Clinical|December 18, 2015
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersTarek M A Abdel-Fatah, Arvind Arora, Paul Moseley, et al.
Breast Cancer Research and Treatment|November 21, 2013
Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapyTarek M A Abdel-Fatah, Nada Albarakati, Lara Bowell, et al.
Oncotarget|January 20, 2018
The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2Tarek M A Abdel-Fatah, Robert C Rees, A Graham Pockley, et al.
Breast Cancer Research and Treatment|June 29, 2014
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancersTarek Abdel-Fatah, Arvind Arora, Devika Agarwal, et al.
Gynecologic Oncology|February 25, 2019
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancersKatia A Mesquita, Muslim Alabdullah, Michaela Griffin, et al.
Pageof 2